O Ringden

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi request reprint Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease
    Olle Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 81:1390-7. 2006
  2. doi request reprint A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation
    O Ringden
    Division of Therapeutic Immunology and Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden
    J Intern Med 274:153-62. 2013
  3. doi request reprint Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host disease
    Olle Ringden
    Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Biol Blood Marrow Transplant 19:314-20. 2013
  4. doi request reprint Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease
    Olle Ringden
    Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden
    Stem Cells 31:592-601. 2013
  5. doi request reprint Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients
    O Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Intern Med 272:472-83. 2012
  6. ncbi request reprint Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders
    Olle Ringden
    Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Eur J Haematol 87:503-9. 2011
  7. doi request reprint Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic bone marrow transplantation
    Olle Ringden
    Centre for Allogeneic Stem Cell Transplantation and Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Br J Haematol 157:220-9. 2012
  8. ncbi request reprint Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon
    O Ringden
    Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Leukemia 21:2271-6. 2007
  9. doi request reprint The allogeneic graft-versus-cancer effect
    Olle Ringden
    Centre for Allogeneic Stem Cell Transplantation and Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Br J Haematol 147:614-33. 2009
  10. pmc The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation
    Olle Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Blood 113:3110-8. 2009

Collaborators

Detail Information

Publications146 found, 100 shown here

  1. ncbi request reprint Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease
    Olle Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 81:1390-7. 2006
    ..Mesenchymal stem cells (MSC) have immunomodulatory effects. The aim was to study the effect of MSC infusion on graft-versus-host disease (GVHD)...
  2. doi request reprint A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation
    O Ringden
    Division of Therapeutic Immunology and Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden
    J Intern Med 274:153-62. 2013
    ..To our knowledge, no randomized toxicity studies have been conducted to compare myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) in allogeneic haematopoietic stem cell transplantation (HSCT)...
  3. doi request reprint Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host disease
    Olle Ringden
    Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Biol Blood Marrow Transplant 19:314-20. 2013
    ..98; P = .13). Five-year survival was 61% in the home care group as compared with 49% in the control subjects (P = .07). Home care is safe. Home care and many days spent at home were correlated with a low risk of acute GVHD...
  4. doi request reprint Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease
    Olle Ringden
    Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden
    Stem Cells 31:592-601. 2013
    ..Two patients showed no response at all. Three patients are alive from 6 to 21 months after HSCT. One patient is well and two have chronic GVHD. Thus, FMCs may be successfully used for immune modulation and tissue repair...
  5. doi request reprint Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients
    O Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Intern Med 272:472-83. 2012
    ..No survival benefit of using blood stem cells instead of bone marrow (BM) has been shown in matched unrelated donor (MUD) transplantation...
  6. ncbi request reprint Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders
    Olle Ringden
    Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Eur J Haematol 87:503-9. 2011
    ..47). Survival at 5 yr was 95% and 92%. Thus, sirolimus combined with tacrolimus is a promising immunosuppressive regimen in HSCT, also for non-malignancies, and its efficacy should be confirmed in prospective clinical trials...
  7. doi request reprint Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic bone marrow transplantation
    Olle Ringden
    Centre for Allogeneic Stem Cell Transplantation and Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Br J Haematol 157:220-9. 2012
    ..Prophylaxis with growth factor increases the risk of GVHD, does not affect relapse, increases NRM and reduces LFS > 10 years after HSCT, regardless of conditioning with TBI...
  8. ncbi request reprint Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon
    O Ringden
    Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Leukemia 21:2271-6. 2007
    ..A patient with steroid-resistant graft-versus-host disease of the gut experienced perforated diverticulitis and peritonitis that was reversed twice by MSC. MSC is a novel treatment for therapy-induced tissue toxicity...
  9. doi request reprint The allogeneic graft-versus-cancer effect
    Olle Ringden
    Centre for Allogeneic Stem Cell Transplantation and Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Br J Haematol 147:614-33. 2009
    ..This paper reviews the current knowledge in graft-versus-cancer effects. Future directions, such as immunotherapy using leukaemia-specific CTLs, allo-depleted T-cells and suicide gene manipulated T-cells, are presented...
  10. pmc The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation
    Olle Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Blood 113:3110-8. 2009
    ..In conclusion, risk of relapse was the same (ALL, CML) or worse (AML) in URD transplant recipients compared with HLA-identical sibling transplant recipients, suggesting a similar GVL effect...
  11. ncbi request reprint Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases
    O Ringden
    Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Bone Marrow Transplant 39:383-8. 2007
    ..03). Treatment-related mortality was 4 and 15%, and 5-year survival was 89 and 85% in the FBC and MC groups. Although survival was similar, FBC is a promising alternative to MC in non-malignant disorders...
  12. doi request reprint Unrelated cord blood and mismatched unrelated volunteer donor transplants, two alternatives in patients who lack an HLA-identical donor
    O Ringden
    Centre for Allogeneic Stem Cell Transplantation and Division of Clinical Immunology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Bone Marrow Transplant 42:643-8. 2008
    ..006). Although the material is small and heterogeneous, engraftment was delayed, leukocyte chimerism was not significantly different and survival was superior using UCB rather than MM URD transplants...
  13. doi request reprint Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease
    Olle Ringden
    Division of Clinical Immunology, Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 90:1022-9. 2010
    ..Total body irradiation and bone marrow were found to be prerequisites for acute GVHD. This study encouraged us to perform a retrospective clinical study...
  14. doi request reprint Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages
    O Ringden
    Center for Allogeneic Stem Cell Transplantation, Division of Clinical Immunology, and Hematology Center, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, F79, SE 141 86 Stockholm, Sweden
    Best Pract Res Clin Haematol 24:65-72. 2011
    ..To conclude, MSCs is a novel treatment that may be used for GVHD, tissue toxicity and hemorrhages because of its immune inhibitory and anti-inflammatory effects...
  15. ncbi request reprint An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation
    M Remberger
    Centre for Allogeneic Stem Cell Transplantation, and Department of Clinical Immunology, Karolinska Institute, Huddinge Hospital, Sweden
    Eur J Haematol 66:50-6. 2001
    ..The cumulative probabilities of relapse were 37% in the both groups. This suggests that the Scandinavian population is more homogeneous with regard to minor histocompatibility antigens important for chronic, but not acute GVHD...
  16. ncbi request reprint Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation
    O Ringden
    Center for Allogeneic Stem Cell Transplantation, Department of Clinical Immunology, Huddinge Hospital, Huddinge, Sweden
    Blood 94:455-64. 1999
    ..01). One-year transplant-related mortality was 21% and 27% and survival was 53% and 54% in the BM and PBSC groups, respectively (NS). The 2-year relapse-free survival was 41% and 46% in the two groups, respectively...
  17. ncbi request reprint Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplanta
    O Ringden
    Centre for Allogeneic Stem Cell Transplantation, and the Department of Hematology, Karolinska Institute, Huddinge Hospital, Huddinge, Sweden
    Blood 93:2196-201. 1999
    ..01). In patients with chronic myeloid leukemia (CML) in first chronic phase, 7-year LFS was 72% and 83% in the two groups, respectively...
  18. ncbi request reprint Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells
    K Le Blanc
    Hematology Center, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Leukemia 21:1733-8. 2007
    ..Thus, co-transplantation of MSC resulted in fast engraftment of absolute neutrophil count (ANC) and platelets and 100% donor chimerism, even in three patients regrafted for graft failure/rejection...
  19. ncbi request reprint A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning
    M Hassan
    Laboratory of Hematology, Division of Hematology, Department of Medicine, Huddinge University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 30:833-41. 2002
    ..Moreover, the novel liposomal form of busulphan showed a favorable toxicity profile and seems safe as a part of the high-dose therapy prior to SCT...
  20. ncbi request reprint Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation
    J Mattsson
    Centre for Allogeneic Stem Cell Transplantation and Department of Clinical Immunology, Karolinska Institutet at Huddinge University Hospital, SE 141 86 Stockholm, Sweden
    Br J Haematol 115:935-44. 2001
    ..In conclusion, mixed chimaerism in the T-cell fraction is common at the time of acute GVHD and disease response in patients conditioned with non-myeloablative therapy...
  21. ncbi request reprint Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients
    P Ljungman
    Department of Hematology, Huddinge University Hospital, Karolinska Institutet, Sweden
    Transplantation 66:1330-4. 1998
    ..Several preventive strategies against cytomegalovirus (CMV) disease have been developed during the last decade. These have frequently been used in combination, and it has been difficult to identify each strategy's contribution...
  22. ncbi request reprint Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: a single centre study
    D Hauzenberger
    Department of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Tissue Antigens 72:549-58. 2008
    ..An HLA-C or -DQ mismatch had no significant impact on survival, TRM and relapse. In conclusion, compared with MUD, HLA class I allele mmUD had an increased risk of acute GVHD and TRM...
  23. ncbi request reprint G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV
    M Remberger
    Centre for Allogeneic Stem Cell Transplantation, F79 Huddinge University Hospital, SE 141 86 Stockholm, Sweden
    Bone Marrow Transplant 32:217-23. 2003
    ..In conclusion, G-CSF given after HLA-identical sibling HSCT was associated with a higher risk of grades II-IV acute GVHD, but not transplant-related mortality...
  24. ncbi request reprint N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation
    F Sjöö
    Center for Allogeneic Stem Cell Transplantation, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
    Bone Marrow Transplant 32:349-54. 2003
    ..Increased liver enzymes during conditioning decreased or normalized in all patients. We suggest that NAC therapy is safe and does not impair the myeloablative effect of busulfan during conditioning prior to SCT...
  25. doi request reprint Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI
    K Garming-Legert
    Division of Oral and Maxillofacial Surgery, Department of Dental Medicine, Karolinska Institutet, Huddinge, Sweden
    Oral Dis 17:670-6. 2011
    ..Does conditioning with fractionated total body irradiation (fTBI) or busulfan (Bu) causes less salivary dysfunction compared with single dose (sTBI) after hematopoietic stem cell transplantation (HSCT)...
  26. ncbi request reprint Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer
    O Ringden
    Department of Clinical Immunology, Karolinska Institutet, Huddinge Hospital, Sweden
    Transplantation 69:2043-8. 2000
    ..We investigated whether it were possible to induce mixed chimerism and obtain an antitumor effect in a patient with a large primary liver cancer after combined liver and bone marrow transplantation (BMT)...
  27. ncbi request reprint T-cell receptor Vbeta repertoire after myeloablative and reduced intensity conditioning allogeneic haematopoietic stem cell transplantation
    P Hentschke
    Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden
    Scand J Immunol 61:285-94. 2005
    ..GVHD, infections and age are more important for immune reconstitution than type of conditioning...
  28. ncbi request reprint High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients
    P Ljungman
    Department of Haematology, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
    Br J Haematol 111:774-81. 2000
    ..04) influenced HHV-6 DNA levels. HHV-6 viral load was significantly correlated with delayed platelet engraftment in both univariate (P < 0.01) and multivariate analysis, and to the number of platelet transfusions...
  29. ncbi request reprint The graft-versus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors
    M Remberger
    Department of Clinical Immunology, Huddinge University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 30:761-8. 2002
    ..Overall and relapse-free survival were not improved by the occurrence of acute GVHD...
  30. doi request reprint Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT
    O Blennow
    Division of Infectious Diseases, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 45:1710-8. 2010
    ..In this study, PCR on peripheral blood was a poor indicator of IFI early after RIC HSCT. Aspergillus PCR tests performed on clinical suspicion after day 100 were insufficiently sensitive to be diagnostically useful...
  31. ncbi request reprint Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells
    C Gotherstrom
    Division of Clinical Immunology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 32:265-72. 2003
    ..fMSC inhibit lymphocyte proliferation induced by mitogens, but not alloreactivity as measured by MLC...
  32. doi request reprint Cytotoxic crossmatch analysis before allo-SCT is a poor diagnostic tool for prediction of rejection
    J Mattsson
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Bone Marrow Transplant 45:235-8. 2010
    ..In conclusion, the pretransplant cytotoxic T- and/or B-crossmatch is a poor predictor of rejection after allo-SCT...
  33. doi request reprint Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction
    H Omar
    Department of Medicine, Huddinge, Division of Haematology, Karolinska Institutet, Stockholm, Sweden
    Transpl Infect Dis 11:393-9. 2009
    ..The likelihood of PTLD is increased in the presence of specific risk factors. Monitoring of EBV DNA load and early administration of rituximab in patients with high EBV loads is recommended for high-risk patients...
  34. ncbi request reprint Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?
    O Ringden
    Centre for Allogeneic Stem Cell Transplantation, Huddinge, Sweden
    Br J Haematol 111:1130-7. 2000
    ..This may be as a result of a graft-vs.-leukaemia effect in the absence of GVHD...
  35. ncbi request reprint Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation
    H Hagglund
    Departments of Transplantation Surgery, Clinical Immunology, Paediatrics, and Medicine, Karolinska Institute, Huddinge Hospital, Huddinge, Sweden
    Blood 92:4568-72. 1998
    ..02), and conditioning with busulphan (P =.02). Our conclusion is that norethisterone treatment should not be used in patients undergoing BMT and heparin prophylaxis did not affect the incidence or mortality of VOD...
  36. ncbi request reprint Immunotherapy by allogeneic stem cell transplantation
    Olle Ringden
    Division of Clinical Immunology, Karolinska Institutet, Karolinska University, Hospital, Huddinge, SE 141 86 Stockholm, Sweden
    Adv Cancer Res 97:25-60. 2007
    ..Mesenchymal stem cells have immunomodulatory properties and may be used for immunomodulation of GVHD and tissue repair. All things considered, the future looks promising for ASCT...
  37. doi request reprint Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning
    T Mårtensson
    Astrid Lindgren Children s Hospital and Karolinska University Hospital Huddinge, Stockholm, Sweden
    Pediatr Transplant 17:285-93. 2013
    ..5% (five of eight) in the BuCy group. In conclusion, the addition of melphalan to the BuCy conditioning regimen resulted in severe gastrointestinal complications and did not improve overall survival...
  38. ncbi request reprint Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia
    O Ringden
    Centre for Allogeneic Stem Cell Transplantation, Huddinge, Sweden
    J Clin Oncol 20:4655-64. 2002
    ..However, the data are inconsistent with regard to acute and chronic graft-versus-host disease (GVHD), relapse, transplant-related mortality (TRM), and leukemia-free survival (LFS)...
  39. ncbi request reprint Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation
    L Barkholt
    Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden
    Bone Marrow Transplant 40:683-9. 2007
    ..Interindividual variations in CsA uptake and metabolism may explain the wide variation of C2 levels without prediction for increased risk for severe aGVHD or infectious complication when C0 guided the CsA dosing...
  40. ncbi request reprint Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival
    A C Norlin
    Department of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 41:267-73. 2008
    ..04) and an increased incidence of transplant-related mortality (27 vs 9%, P<0.01). IgG levels generally increase after SCT. Persistent low levels of IgG are a risk factor for death after SCT...
  41. ncbi request reprint Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin
    M Remberger
    Department of Clinical Immunology and Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Clin Transplant 15:147-53. 2001
    ..Most patients died of GVHD, with virus or fungal infections as contributing causes of death. To conclude, treatment of severe acute GVHD is difficult and ATG, in our hands, adds nothing to conventional pharmacological treatment...
  42. ncbi request reprint Polyclonal anti-T-cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation
    M Remberger
    Center for Allogeneic Stem Cell Transplantation, Department of Clinical Immunology, F79 Karolinska Institutet, Huddinge University Hospital, Huddinge, SE 141 86 Stockholm, Sweden
    Pediatr Transplant 5:285-92. 2001
    ..01). Hence, the use of polyclonal ATG as part of conditioning prior to ASCT in children is safe and the survival rate encouraging...
  43. ncbi request reprint Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation
    B M Svahn
    Center for Allogeneic Stem Cell Transplantation and the Division of Clinical Immunology, Karolinska Institute, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Bone Marrow Transplant 36:511-6. 2005
    ..04). Home care after ASCT is a novel approach that resulted in less TRM, similar incidence of chronic GVHD and relapse, and improved long-term survival compared to controls treated in the hospital...
  44. doi request reprint Graft failure in the modern era of allogeneic hematopoietic SCT
    R Olsson
    Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 48:537-43. 2013
    ..01). In conclusion, graft failure was only associated with inferior survival in malignant disease. Non-malignant disorders, HLA match, conditioning intensity, immunosuppression regimen and cell dose all influenced graft failure risk...
  45. ncbi request reprint Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors
    M Remberger
    Center for Allogeneic Stem Cell Transplantation, Huddinge University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 29:391-7. 2002
    ..27-0.97, P value = 0.03). No significant difference in the risk of relapse was seen (P = 0.63). This suggests that Thymoglobulin during conditioning may reduce non-relapse mortality after unrelated donor marrow transplantation...
  46. ncbi request reprint Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival
    A Gustafsson Jernberg
    Department of Paediatrics, Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden
    Bone Marrow Transplant 31:175-81. 2003
    ..Acute GVHD was not an independent predictor for relapse or death in this study. This study is in support of a GVL effect in childhood leukaemia related to chronic GVHD, reducing the risk of relapse and improving survival...
  47. ncbi request reprint Cytolytic T cell reactivity to Epstein-Barr virus is lost during in vitro T cell expansion
    S Carlens
    The Centre for Allogeneic Stem Cell Transplantation and Department of Microbiology, Pathology and Clinical Immunobiology, Huddinge University Hospital, Stockholm, Sweden
    J Hematother Stem Cell Res 11:669-74. 2002
    ....
  48. doi request reprint Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells
    H Samuelsson
    Karolinska Institutet, Stockholm, Sweden
    Cytotherapy 11:129-36. 2009
    ..We investigated the impact of freezing and prolonged storage on cell viability, proliferation and immunosuppression in vitro...
  49. ncbi request reprint No impact of NOD2/CARD15 on outcome after SCT
    D Sairafi
    Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 41:961-4. 2008
    ..On the basis of these findings we conclude that a consideration to NOD2/CARD15 mutation status is not pertinent when selecting a donor for Allo-SCT at our centre...
  50. ncbi request reprint Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study
    M Remberger
    Department of Clinical Immunology and Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 41:399-405. 2008
    ..1%, while it was 38.0 and 85.0% in patients with one (n=29) or two (n=10) risk factors (P<0.001). We concluded that risk factors for acute GVHD using RIC are similar as using myeloablative conditioning...
  51. ncbi request reprint Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients
    P Ljungman
    Department of Hematology, Karolinska University Hospital, Stockholm 14186, Sweden
    Bone Marrow Transplant 34:1067-9. 2004
    ..07). A total of 14 patients received a booster dose of an inactivated poliovirus vaccine and all responded. We conclude that poliovirus immunity is retained long term after revaccination in most patients after allogeneic SCT...
  52. doi request reprint GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants
    Richard Olsson
    Centre for Allogeneic Stem Cell Transplantation, Karolinska Institute, Karolinska University Hospital, Huddinge, Sweden
    Eur J Haematol 84:323-31. 2010
    ....
  53. ncbi request reprint Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care
    Britt Marie Svahn
    Centre for Allogeneic Stem Cell Transplantation, Department of Clinical Immunology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Blood 100:4317-24. 2002
    ..03). To conclude, home care after SCT is a novel and safe approach. This study found it to be advantageous, compared with hospital care...
  54. ncbi request reprint Reduced risk for extensive chronic graft-versus-host disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalovirus
    Kajsa Larsson
    Division for Hematology, Department of Medicine, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
    Transplantation 77:526-31. 2004
    ..The aim of this study was to investigate the relationship between cytomegalovirus (CMV) and extensive chronic graft-versus-host disease (GvHD) after allogeneic stem-cell transplantation (SCT)...
  55. ncbi request reprint Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?
    Olle Ringden
    Centre for Allogeneic Stem Cell Transplantation, Division of Clinical Immunology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Biol Blood Marrow Transplant 10:128-34. 2004
    ..The 5-year survival was 72%, 48%, and 30% with 0, 1, and 2 risk factors, respectively. We concluded that unrelated hematopoietic stem cell transplantation may be improved if an optimal donor and immunosuppression are chosen...
  56. ncbi request reprint Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma
    P Hentschke
    Center for Allogenic Stem Cell Transplantation and Division of Immunology, Microbiology and Pathology, Huddinge University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 31:253-61. 2003
    ..However, the regression of some metastases associated with GVHD provides suggestive evidence that the GVHD effect may occur in renal and colon adenocarcinoma using reduced intensity conditioning...
  57. ncbi request reprint The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation
    C Nilsson
    Department of Medicine, Huddinge University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 31:429-35. 2003
    ..We conclude that metronidazole should not be administered simultaneously with Bu to avoid the high plasma levels of Bu, which may lead to severe toxicity and/or treatment related mortality...
  58. ncbi request reprint Viridans streptococcal septicaemia in neutropenic patients: role of proinflammatory cytokines
    N Ihendyane
    Department of Medicine, Center for Infectious Medicine, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 33:79-85. 2004
    ..04). The study underscores the importance of the host-pathogen interplay in determining the level of inflammation, and hence the severity of disease...
  59. ncbi request reprint No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors
    M Remberger
    Centre for Allogeneic Stem Cell Transplantation and Department of Clinical Immunology, Huddinge University Hospital, Stockholm, Sweden
    Blood 98:1739-45. 2001
    ..PBSC from HLA-compatible unrelated donors can be used safely as an alternative to BM for stem cell transplantation...
  60. doi request reprint Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation
    B M Svahn
    Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet and Karolinska University Hospital Huddinge, Stockholm, Sweden
    Bone Marrow Transplant 47:706-15. 2012
    ..To conclude, major complications increased the costs of HSCT. Unrelated donor transplants were more expensive than HLA-identical sibling transplants. Costs were reduced in patients treated with NMC...
  61. doi request reprint Disturbances in dental development and craniofacial growth in children treated with hematopoietic stem cell transplantation
    M Vesterbacka
    Division of Orthodontics and Pediatric Dentistry, Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden
    Orthod Craniofac Res 15:21-9. 2012
    ..To investigate the correlation between age, degree of disturbances in dental development, and vertical growth of the face in children treated with hematopoietic stem cell transplantation (HSCT)...
  62. ncbi request reprint Reconstitution of the Ig heavy chain CDR3 repertoire after allogeneic haematopoietic stem cell transplantation with myeloablative or reduced-intensity conditioning regimens
    B Omazic
    Arvid Wretlind Laboratory at the Center for Surgical Sciences, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Scand J Immunol 61:72-81. 2005
    ..The conditioning regimen may be of importance, but data from this study suggest that individual factors and the various complications occurring after HSCT are more likely to determine the development of the B-lymphocyte repertoire...
  63. doi request reprint Hematopoietic stem cell transplantation in severe congenital neutropenia
    G Carlsson
    Childhood Cancer Research Unit, Department of Women s and Children s Health, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Pediatr Blood Cancer 56:444-51. 2011
    ..SCN is also a premalignant condition; a significant proportion of patients develop myelodysplastic syndrome or leukemia (MDS/L). Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for SCN...
  64. doi request reprint Allogeneic hematopoietic SCT in patients with non-malignant diseases, and importance of chimerism
    P Svenberg
    Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 44:757-63. 2009
    ..We conclude that patients with non-malignant diseases, who develop MC after transplant have less acute GVHD. Despite the high incidence of MC, overall survival is promising...
  65. ncbi request reprint Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease
    P Ljungman
    Department of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Bone Marrow Transplant 34:589-93. 2004
    ..Since measles is again circulating in many countries and measles is a serious infection after SCT, vaccination should be considered...
  66. pmc NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation
    Andreas T Björklund
    Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Blood 115:2686-94. 2010
    ..Our results provide evidence against the emergence of alloreactive NK cells in HLA-identical allogeneic SCT...
  67. ncbi request reprint Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT
    G Avetisyan
    Division of Haematology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    Bone Marrow Transplant 40:865-9. 2007
    ..01). There was no effect as regards the type of conditioning, donor type, stem cell source or acute GVHD. Monitoring the immunity of SCT patients may allow more targeted use of antiviral therapy...
  68. pmc Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma
    O Ringden
    Department of Clinical Immunology, Karolinska University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 47:831-7. 2012
    ..52, P=0.001). The reduction in relapse risk associated with cGVHD is consistent with a beneficial graft-vs-myeloma effect, but this did not translate into a survival advantage...
  69. ncbi request reprint Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual
    M Sundin
    Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    Bone Marrow Transplant 37:1051-9. 2006
    ..However, MSC may be susceptible to infection if infused in a patient with CMV or HSV-1 viremia. MSC transplantation may compromise the host's defense against infectious agents...
  70. ncbi request reprint Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation
    A Bjorklund
    Hematology Center, Karolinska University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 40:1055-62. 2007
    ..In conclusion, infections occurring later than 6 months after HSCT are important contributors to late non-relapse mortality after HSCT. CMV infection or acute GVHD markedly increase the risk...
  71. doi request reprint A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation
    L Barkholt
    Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Bone Marrow Transplant 41:785-90. 2008
    ..There were two patients in the NAC group who developed VOD, as compared to three of the controls. To conclude, NAC does not improve liver toxicity after ASCT...
  72. doi request reprint No increased trapping of multipotent mesenchymal stromal cells in bone marrow filters compared with other bone marrow cells
    M Sundin
    Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Cytotherapy 10:238-42. 2008
    ..It has been suggested that MSC may be trapped in bone marrow (BM) filters during the stem cell procurement and lost from the HSC graft...
  73. ncbi request reprint Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors
    Mats Remberger
    Centre for Allogeneic Stem Cell Transplantation and Department of Clinical Immunology, Karolinska University Hospital, Stockholm, Sweden
    Blood 105:548-51. 2005
    ..In conclusion, PBSCs from HLA-compatible unrelated donors results in similar outcome compared to BM but implies an increased risk for extensive chronic GVHD...
  74. ncbi request reprint Clinical tolerance after allogeneic hematopoietic stem cell transplantation: a study of influencing factors
    Patrik Hentschke
    Centre for Allogeneic Stem Cell Transplantation, Huddinge University Hospital, Stockholm, Sweden Patrik Hentschke transpl hs sll se
    Transplantation 73:930-6. 2002
    ..However, this phenomenon has rarely been studied...
  75. ncbi request reprint Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    Mats Remberger
    Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Biol Blood Marrow Transplant 8:674-82. 2002
    ..Patients with previous acute GVHD grades II to IV may benefit from more aggressive initial treatment. This possibility would have to be examined in clinical trials...
  76. doi request reprint Sequential Organ Failure Assessment predicts the outcome of SCT recipients admitted to intensive care unit
    K Gilli
    Department for Anaesthesiology and Intensive Care Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Bone Marrow Transplant 45:682-8. 2010
    ..01). In multivariate analysis of death, SOFA score was the only significant factor (P<0.001). In conclusion, SOFA score predicted prognosis in ASCT patients treated at the ICU...
  77. pmc Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro
    H Karlsson
    Division of Clinical Immunology and Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet and Karolinska University Hospital Huddinge, Stockholm, Sweden
    Clin Exp Immunol 167:543-55. 2012
    ..Fetal membrane may provide a valuable source of cells with immunosuppressive properties and could possibly be used for treatment of acute GVHD and other inflammatory disorders...
  78. ncbi request reprint Immunomodulation by mesenchymal stem cells and clinical experience
    K Le Blanc
    Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Intern Med 262:509-25. 2007
    ..Possible clinical applications include therapy-resistant severe acute graft-versus-host disease, tissue repair, treatment of rejection of organ allografts and autoimmune disorders...
  79. ncbi request reprint The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse
    S Carlens
    Centre for Allogeneic Stem Cell Transplantation, Huddinge University Hospital, Sweden
    Biol Blood Marrow Transplant 7:31-8. 2001
    ..022). This study emphasizes the importance of early disease stage and presence of chronic GVHD for effective DLI...
  80. ncbi request reprint Mesenchymal stem cells stimulate antibody secretion in human B cells
    I Rasmusson
    Karolinska Institutet, Division of Clinical Immunology, Stockholm, Sweden
    Scand J Immunol 65:336-43. 2007
    ..To conclude, MSC stimulate B-cell antibody secretion. The IgG secretion by activated B cells may be stimulated or inhibited by the addition of MSC, depending on the level of stimulation...
  81. doi request reprint BK-viruria and haemorrhagic cystitis are more frequent in allogeneic haematopoietic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts
    G Giraud
    Department of Oncology Pathology, Karolinska Institutet, Stockholm, Sweden
    Bone Marrow Transplant 41:737-42. 2008
    ..6; P=0.03). However, when analysing HSCT performed with URD or RD grafts separately, BKV (OR 8.5; 95% CI 1.8-19.3; P=0.004) and MC (OR 5.9; 95% CI 1.3-11.3; P=0.009) increased the risk for HC only with a URD, but not with an RD graft...
  82. ncbi request reprint Risk factors in pediatric stem cell transplantation for leukemia
    Asa Gustafsson Jernberg
    Department of Pediatrics, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Pediatr Transplant 8:464-74. 2004
    ..39) and death (RR 0.42). We conclude that in children with leukemia other specific donor characteristics such as HLA-matching, gender, parity, and exposure to herpes viruses were more important for outcome than relationship...
  83. ncbi request reprint Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation
    Mehmet Uzunel
    Department of Clinical Immunology, Center for Allogeneic Stem Cell Transplantation CAST, Stockholm, Sweden
    Blood 101:469-72. 2003
    ..In conclusion, molecular remission can be induced in most patients after NST, albeit with different kinetics from CST...
  84. ncbi request reprint Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
    Katarina Le Blanc
    Division of Clinical Immunology and Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Lancet 363:1439-41. 2004
    ..Clinical response was striking. The patient is now well after 1 year. We postulate that mesenchymal stem cells have a potent immunosuppressive effect in vivo...
  85. ncbi request reprint Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation
    Mats Remberger
    Department of Clinical Immunology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden
    Transplantation 78:122-7. 2004
    ..Thymoglobulin given before allo-hematopoietic stem-cell transplantation (HSCT) from unrelated donors reduces acute graft-versus-host disease (GvHD), but the optimal dose is unknown...
  86. ncbi request reprint A low body mass index is correlated with poor survival after allogeneic stem cell transplantation
    Katarina Le Blanc
    Center for Allogeneic Stem Cell Transplantation, Division of Clinical Immunology, F79, Karolinska Institutet, Huddinge University Hospital, SE 141 86, Stockholm, Sweden
    Haematologica 88:1044-52. 2003
    ..The purpose of this study was to determine whether body mass index (BMI, kg body weight/height (in m2) is related to survival in recipients of allogeneic stem cell transplantation (ASCT)...
  87. ncbi request reprint Is it safe to treat allogeneic stem cell transplanted recipients at home during the pancytopenic phase? A pilot trial
    B M Svahn
    Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Huddinge Hospital B87, SE 141 86 Huddinge, Sweden
    Presse Med 33:474-8. 2004
    ..After myeloablative treatment and allogeneic stem cell transplantation (ASCT), patients are kept isolated in the hospital to prevent infections during neutropenia...
  88. doi request reprint Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation
    L von Bahr
    Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine Hematology Center, Karolinska University Hospital, Stockholm, Sweden
    Stem Cells 30:1575-8. 2012
    ..We conclude that MSCs appear to mediate their function through a "hit and run" mechanism. The lack of sustained engraftment limits the long-term risks of MSC therapy...
  89. doi request reprint Salivary secretion in children after fractionated or single-dose TBI
    K Garming Legert
    Department of Dental Medicine, Division of Oral and Maxillofacial Surgery, Karolinska Institute, Huddinge, Sweden
    Bone Marrow Transplant 47:404-10. 2012
    ..49, 95% confidence interval (CI)=1.40-30, P=0.014) and seropositivity of the recipient for 3-4 herpesviruses (OR=6.57, 95% CI=1.26-34, P=0.021) and a low stimulated salivary secretion rate (<0.5 mL/min) was found 1 year after HSCT...
  90. ncbi request reprint PCR and other non-culture methods for diagnosis of invasive Candida infections in allogeneic bone marrow and solid organ transplant recipients
    E Chryssanthou
    Department of Laboratory Medicine, Karolinska Institute and Hospital, Stockholm, Sweden
    Mycoses 42:239-47. 1999
    ..Combination of several non-culture assays is needed to diagnose invasive fungal infection in high-risk transplant recipients. No single test was sufficient for diagnosis...
  91. ncbi request reprint The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia
    M Uzunel
    Department of Clinical Immunology, Karolinska Institute at Huddinge University Hospital, Huddinge, Sweden
    Blood 98:1982-4. 2001
    ..005). In conclusion, for patients entering transplantation while they have residual disease, a combination of acute and chronic graft-versus-host disease may be needed to decrease the risk of relapse after SCT...
  92. ncbi request reprint A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation
    Katarina Le Blanc
    Centre for Allogeneic Stem Cell Transplantation and Division of Clinical Immunology, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
    Transplantation 78:1014-20. 2004
    ..Nonmyeloablative (NM) conditioning and reduced-intensity conditioning (RIC) are increasingly used for allogeneic hematopoietic stem-cell transplantation. Such regimens have not been compared...
  93. ncbi request reprint Allogenic stem cell transplantation for nonmalignant disorders using matched unrelated donors
    Petter Svenberg
    Centre for Allogenic Stem Cell Transplantation, Department of Paediatrics, Karolinska University Hospital, Huddinge, SE 14186 Stockholm, Sweden
    Biol Blood Marrow Transplant 10:877-82. 2004
    ..We conclude that HSCT with HLA-A, -B, and -DRbeta1 genomically matched unrelated donors in combination with antithymocyte globulin in the conditioning regimen gives encouraging results in patients with SAA or IEM...
  94. ncbi request reprint Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia
    Mehmet Uzunel
    Department of Clinical Immunology and Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sweden
    Br J Haematol 122:788-94. 2003
    ..05). In conclusion, MRD detection after SCT is correlated with relapse and provides the opportunity for initiating immunotherapeutic intervention at an early stage when the tumour cell burden is still low...
  95. ncbi request reprint Use of mesenchymal stem cells for the prevention of immune complications of hematopoietic stem cell transplantation
    Katarina Le Blanc
    Division of Clinical Immunology, F79 Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Haematologica 90:438. 2005
  96. ncbi request reprint Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood a
    Olle Ringden
    Centre for Allogeneic Stem Cell Transplantation, Division of Clinical Immunology F79, Karolinska Institute, Huddinge University Hospital, SE 141 86 Stockholm, Sweden
    J Clin Oncol 22:416-23. 2004
    ..Granulocyte colony-stimulating factor (G-CSF) is given after bone marrow transplantation (BMT) to shorten the neutropenic phase. Its effects have not been evaluated in a large patient population...
  97. ncbi request reprint Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia
    Anna Nordlander
    Center for Allogenic Stem Cell Transplantation and Department of Clinical Immunology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Biol Blood Marrow Transplant 10:195-203. 2004
    ..01), and an HLA-matched donor (P=.01). The association between herpes simplex virus infection and a low frequency of relapse is a new observation and may indicate that viral antigens play a role in the induction of an antileukemic effect...
  98. doi request reprint A randomized study of buffy coat platelets in platelet additive solution stored 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic haematopoietic progenitor cell transplant recipients
    B Diedrich
    Departments of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital at Huddinge, Stockholm, Sweden
    Vox Sang 97:254-9. 2009
    ..To provide additional verification, randomized patient transfusion studies are needed...
  99. ncbi request reprint Treatment costs and survival in patients with grades III-IV acute graft-versus-host disease after allogenic hematopoietic stem cell transplantation during three decades
    Britt Marie Svahn
    Center for Allogeneic Stem Cell Transplantation and Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Transplantation 81:1600-3. 2006
    ..It was found that the time the patients had GVHD did not differ among the three groups. In conclusion, the costs and survival rates associated with severe acute GVHD has increased in recent years...
  100. ncbi request reprint Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes
    K Le Blanc
    Division of Clinical Immunology, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
    Scand J Immunol 60:307-15. 2004
    ..In summary, human MSC suppress proliferation of both CD4+ and CD8+ lymphocyte and decrease the expression of activation markers...